Nurix Therapeutics Inc (NRIX) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and...

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities